Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation and use of 6-hydroxydideoxyguanosine phosphate

A dideoxy and triphosphate technology, applied in the field of drug research, can solve the problems of poor fat solubility, poor liver targeting, poor affinity, etc., and achieve the effect of increasing concentration and increasing fat solubility

Active Publication Date: 2017-05-31
NANJING GRITPHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] From the pharmacy and pharmacological research experiments of 6-methoxy-2', 3'-dideoxyguanosine reported so far, the existing 6-methoxy-2', 3'-dideoxyguanosine Nucleoside compounds have many problems: for example, they are easily decomposed in vivo and have insufficient activity; they have poor fat solubility and are not easy to penetrate cell membranes; they have poor affinity with nucleoside kinases that can activate nucleosides, resulting in ineffective Easily converted to active form - dideoxynucleoside triphosphate; poor liver targeting, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and use of 6-hydroxydideoxyguanosine phosphate
  • Preparation and use of 6-hydroxydideoxyguanosine phosphate
  • Preparation and use of 6-hydroxydideoxyguanosine phosphate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0177] Example 1 Preparation of compound (III)

[0178] Add dry DMF (60ml) into a 500mL three-neck flask, start stirring and add compound II (26.77g, content 99%, 0.10mol), Cbz-Cl (17.06g, 0.10mol). Cool to 10°C under stirring, keep in the range of 0 to 10°C, add pyridine (15.82g, 0.20mol) dropwise, and let it rise to room temperature for 1 hour after the dropwise reaction. 240 mL of purified water was added to the reaction liquid, followed by extraction with 120 mL of dichloromethane while stirring. Liquid extraction was carried out, and the aqueous layer was extracted once with 120 mL of dichloromethane. The organic layers were combined, washed with saturated brine, and dried over anhydrous magnesium sulfate (100 g). After filtration, the filtrate was concentrated under reduced pressure to recover dichloromethane to obtain 37.81 g of oily liquid with a yield of 94.1%. ESI-MS ( m / z ): 402.7 [M+H] + ; HPLC purity: 98.6%.

Embodiment 2

[0179] Embodiment 2 Preparation of compound (Ⅳ)

[0180] Add compound III (36.16 g, content 98.6%, 0.090 mol), benzyl chloride (11.40 g, 0.090 mol) and DMF (80 mL) into a 500 mL three-necked flask. Silver oxide (0.5 g) was added with stirring, and the reaction was maintained at 25°C for 6 hours. Add 320 mL of purified water, filter, and discard the filter residue. The pH of the filtrate was adjusted to neutral with sodium hydroxide while stirring. 120 mL of ethyl acetate was added for liquid separation extraction, and the aqueous layer was extracted once with 120 mL of fresh ethyl acetate. The organic layers were combined, washed with saturated brine, and dried over anhydrous magnesium sulfate (120 g). After filtration, the filtrate was concentrated under reduced pressure to recover ethyl acetate to obtain 36.90 g of oily liquid with a yield of 83.3%. ESI-MS ( m / z ): 493.0 [M+H] + ; HPLC purity: 97.5%.

Embodiment 3

[0181] The preparation of embodiment 3 compound (Ⅴ)

[0182] Compound IV (35.42 g, 0.072 mol), the product of Example 2, was added into a 500 mL three-necked flask, and 180 mL of anhydrous methanol was added, and dissolved completely under stirring. Add 10% sodium hydroxide (60.0 g, 0.15 mol) and heat to reflux for 2 hours. Sampling for TLC analysis. After the reaction was completed, the temperature was lowered to room temperature, and extracted with 120 ml of dichloromethane. The aqueous layer was extracted again with 120 ml of dichloromethane, and the combined organic layers were dried by adding anhydrous magnesium sulfate (80 g). After filtration, the filtrate was concentrated under reduced pressure, and dichloromethane was recovered to obtain 22.40 g of light yellow solid with a yield of 91.7%. ESI-MS ( m / z ): 340.3 [M+H] + ; HPLC purity: 97.2%.

[0183] TLC development conditions: ethyl acetate / petroleum ether=1:2 (V / V)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the drug research field, and provides a compound represented by the formula shown in the description and salts thereof; wherein in the formula, the R1 and R2 represent an alkyl group, an aryl group, or an H atom, the R3 represents a carboxyl group or an aryl group, and the X represents an oxygen atom or a NH group. The invention further provides a preparation method, a preparation intermediate and a pharmaceutical composition of the compound. The provided 6-hydroxyl-2',3'-dideoxyguanosine phosphate or derivatives has the characteristics of very good liver targeting property, in-vivo pharmaceutical stability and high activity, low toxicity on other organs, and good druggability.

Description

technical field [0001] The invention belongs to the technical field of drug research, and in particular relates to a 6-hydroxy-2',3'-dideoxyguanosine phosphate compound and its preparation and application. The compound has good liver targeting, stable drug in vivo and It has the characteristics of high activity, low toxicity to other organs, and good druggability. Background technique [0002] Hepatitis B virus (HBV) is a virus that seriously endangers human health. The virus can cause chronic hepatitis, resulting in a high risk of death from liver cirrhosis and liver cancer. According to the statistics of the World Health Organization (WHO), about 2 billion people worldwide have been infected with the virus, of which about 350 million people are chronically infected. It is estimated that more than 600,000 people die from acute or chronic hepatitis B every year. Although HBV infection has been prevented by large-scale inoculation of hepatitis B vaccine, the prevention and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07H19/213C07H19/207C07H1/00A61K31/7076A61P31/20A61P1/16A61P29/00
Inventor 霍立茹赵卿周静
Owner NANJING GRITPHARMA CO LTD